As the world's biggest biotech hub, funding for early-stage startups has long been the lifeblood of Boston's life sciences industry. But the latest figures make for concerning reading—with average seed funding secured by a preclinical start-up plunging 40% over the past year.
In fact, the average seed round for a Massachusetts-based biotech in the first six months of 2026 was just $4.65 million, down from $7.65 million for the same period in 2025, according to the most recent industry snapshot from trade group MassBio. READ MORE
